1. Home
  2. STTK vs FINW Comparison

STTK vs FINW Comparison

Compare STTK & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$2.60

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo FinWise Bancorp

FINW

FinWise Bancorp

N/A

Current Price

$18.49

Market Cap

242.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
FINW
Founded
2016
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
242.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
STTK
FINW
Price
$2.60
$18.49
Analyst Decision
Buy
Buy
Analyst Count
5
3
Target Price
$4.00
$21.67
AVG Volume (30 Days)
171.3K
11.1K
Earning Date
11-06-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.05
Revenue
$1,000,000.00
$80,198,000.00
Revenue This Year
N/A
$72.14
Revenue Next Year
N/A
$47.30
P/E Ratio
N/A
$17.05
Revenue Growth
N/A
14.76
52 Week Low
$0.69
$13.49
52 Week High
$2.71
$22.49

Technical Indicators

Market Signals
Indicator
STTK
FINW
Relative Strength Index (RSI) 71.07 47.82
Support Level $1.93 $17.77
Resistance Level $2.18 $18.04
Average True Range (ATR) 0.18 0.56
MACD 0.07 0.00
Stochastic Oscillator 97.78 23.53

Price Performance

Historical Comparison
STTK
FINW

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: